```html

Utero‑Ovarian Cancer – Comprehensive Medical Guide

Overview

Utero‑ovarian cancer is a term that collectively refers to malignant tumors arising in the uterus (including the endometrium and cervix) and the ovaries. Although each organ has distinct tumor types, they share overlapping risk factors, symptoms, and treatment pathways, which is why many clinical resources group them together for patient education.

• Prevalence: In the United States, uterine (endometrial) cancer accounts for about 4% of all new cancer cases and ovarian cancer roughly 1.3% of all cancers each year. Worldwide, an estimated 417,000 women are diagnosed with uterine cancer and 313,000 with ovarian cancer annually (WHO, 2023).
• Age & gender: These cancers affect only people assigned female at birth, with median diagnosis ages of 62 years for uterine cancer and 63 years for ovarian cancer. However, 10–15 % of ovarian cancers occur in women under 50, and hereditary syndromes can cause cancers in young adults.
• Geography: Incidence is highest in North America, Europe, and Oceania, and lower in sub‑Saharan Africa and parts of Asia, reflecting differences in obesity, reproductive patterns, and genetics.

Symptoms

Early-stage disease often produces vague or no symptoms, which contributes to delayed diagnosis. Below is a complete list of common and less‑common signs, with brief explanations.

Uterine (Endometrial) Cancer Symptoms

• Abnormal uterine bleeding – bleeding between periods, heavy periods, or post‑menopausal bleeding (most common presenting sign).
• Painful intercourse (dyspareunia) – especially if the tumor involves the cervix.
• Pelvic pain or pressure – may feel like a dull ache or a sense of fullness.
• Unexplained weight loss – loss of appetite and sudden weight loss may indicate advanced disease.
• Changes in bowel or bladder habits – constipation, urgency, or frequency if the tumor presses on nearby organs.

Ovarian Cancer Symptoms

• Abdominal bloating or swelling – persistent feeling of fullness, even after a small meal.
• Pelvic or abdominal pain – can be intermittent or constant, often worse after eating.
• Early satiety – feeling full quickly, leading to reduced food intake.
• Changes in urinary frequency – especially at night.
• Back pain – may be referred from deep pelvic structures.
• Unexplained weight loss or gain – due to fluid buildup (ascites) or metabolic changes.
• Fatigue – chronic tiredness not improved by rest.

When any of these symptoms are new, persistent (lasting > 2 weeks), or worsening, medical evaluation is warranted.

Causes and Risk Factors

Both uterine and ovarian cancers are multifactorial. Understanding the underlying mechanisms can help identify who is most at risk.

Genetic Factors

• BRCA1/BRCA2 mutations – increase ovarian cancer risk 10‑ to 20‑fold.
• Hereditary non‑polyposis colorectal cancer (Lynch syndrome) – raises risk for endometrial cancer up to 40‑fold.
• Other rare syndromes – such as Peutz‑Jeghers, Cowden, and hereditary breast‑ovarian cancer syndrome.

Hormonal & Reproductive Factors

• Prolonged exposure to estrogen without progesterone (e.g., early menarche, late menopause, nulliparity, infertility).
• Polycystic ovary syndrome (PCOS) – linked to both endometrial hyperplasia and ovarian cancer.
• Use of tamoxifen for breast cancer – modestly raises uterine cancer risk.

Lifestyle & Environmental Factors

• Obesity (BMI ≥ 30) – adipose tissue converts androgens to estrogen, driving endometrial proliferation; also linked to ovarian cancer.
• Smoking – increases risk of mucinous ovarian tumors and cervical involvement.
• Diet low in fruits/vegetables and high in red meat – associated with modest risk elevation.
• Radiation exposure to the pelvis (e.g., prior pelvic radiotherapy).

Medical History

• History of endometrial hyperplasia, especially with atypia.
• Previous breast cancer (especially with BRCA mutations).
• Infertility treatments involving ovulation induction – may slightly raise ovarian cancer risk.

Diagnosis

A stepwise approach is used to confirm cancer, stage its extent, and plan treatment.

Initial Evaluation

• History & physical exam – detailed symptom review, gynecologic exam, and assessment of lymph nodes.
• Pap smear & HPV testing – mainly for cervical cancer screening; abnormal results may prompt further work‑up.
• Transvaginal ultrasound (TVUS) – first‑line imaging to evaluate uterine thickness and ovarian morphology.

Laboratory Tests

• CA‑125 – serum tumor marker frequently elevated in ovarian cancer; also useful for monitoring response.
• HE4 – another ovarian marker; combined with CA‑125 improves specificity (Risk of Ovarian Malignancy Algorithm – ROMA).
• Endometrial biopsy – office‑based pipelle or hysteroscopic biopsy for suspected uterine cancer.

Imaging for Staging

• Contrast‑enhanced CT scan of abdomen & pelvis – assesses spread to lymph nodes, liver, and peritoneum.
• MRI – superior for local uterine staging (myometrial invasion, cervical spread).
• PET‑CT – helpful in identifying distant metastases or recurrent disease.

Definitive Diagnosis

The gold standard is a surgical pathology specimen obtained during hysterectomy, oophorectomy, or laparoscopy. Histology determines the tumor type (e.g., endometrioid, serous, clear‑cell) and guides targeted therapy.

Treatment Options

Treatment is individualized based on cancer type, stage, patient age, comorbidities, and fertility desires.

Surgery

• Uterine cancer: Total hysterectomy with bilateral salpingo‑oophorectomy (TH/BSO) plus pelvic ± para‑aortic lymphadenectomy for stage II‑IV.
• Ovarian cancer: Comprehensive surgical staging (TAH‑BSO, omentectomy, peritoneal washings, and lymph node sampling). Cytoreductive (debulking) surgery aims to leave no residual disease ≤1 cm.
• Minimally invasive (laparoscopic/robotic) approaches are now standard for early-stage disease.

Radiation Therapy

• External‑beam pelvic radiation or brachytherapy is common after surgery for high‑risk endometrial cancer.
• Whole‑abdominal radiation is rarely used for ovarian cancer today, having been replaced by chemotherapy.

Systemic Therapy

• Chemotherapy: Platinum‑based regimens (carboplatin + paclitaxel) are first‑line for advanced ovarian cancer and high‑risk uterine cancer.
• Hormonal therapy: Progestins or aromatase inhibitors for low‑grade endometrial carcinoma unfit for surgery.
• Targeted agents:
  • PARP inhibitors (olaparib, niraparib, rucaparib) for BRCA‑mutated or homologous‑recombination‑deficient ovarian cancer.
  • Immune checkpoint inhibitors (pembrolizumab) for MSI‑high or POLE‑mutated endometrial tumors.
  • Bevacizumab (VEGF inhibitor) added to chemotherapy in selected ovarian cases.

Adjuvant & Maintenance Therapy

After primary treatment, many patients receive maintenance therapy (e.g., PARP inhibitors for up to 3 years) to delay recurrence, especially in stage III/IV ovarian cancer.

Lifestyle & Supportive Measures

• Nutrition counseling to maintain healthy weight.
• Physical activity programs (150 min moderate exercise/week) improve fatigue and quality of life.
• Psychosocial support—counseling, support groups, and fertility preservation discussions when appropriate.

Living with Utero‑Ovarian Cancer

Managing daily life involves physical, emotional, and practical considerations.

Follow‑up Schedule

• Every 3–4 months for the first 2 years (physical exam, CA‑125 if applicable, imaging as directed).
• Every 6 months during years 3–5, then annually.

Managing Common Side Effects

• Fatigue: Prioritize sleep hygiene, short naps, and low‑impact exercise.
• Nausea: Use anti‑emetics (ondansetron, metoclopramide) before chemotherapy; eat small, bland meals.
• Peripheral neuropathy: Limit exposure to cold, use protective gloves for daily tasks, discuss dose adjustments with oncologist.
• Menopausal symptoms: Non‑hormonal options (vaginal moisturizers, SSRIs) are preferred if on endocrine therapy.

Emotional Well‑Being

Depression and anxiety are common. Access to mental‑health professionals, cancer survivorship programs, and peer support (e.g., GOG, CancerCare) can improve coping.

Fertility Considerations

For women desiring future pregnancy:

• Discuss fertility‑sparing surgery (e.g., uterine‑preserving hysteroscopic resection) for early endometrial cancer.
• Consider oocyte or embryo cryopreservation before chemotherapy.

Practical Tips

• Keep a medication and symptom diary to share with your health‑care team.
• Plan transportation for infusion appointments; ride‑share services or community volunteer drivers can help.
• Utilize financial counseling—many hospitals have programs to assist with insurance and drug costs.

Prevention

While not all cases are preventable, risk can be lowered through modifiable behaviors and surveillance.

• Maintain a healthy weight: Aim for BMI < 25; regular exercise and balanced diet (high fiber, low red meat).
• Use hormonal contraception wisely: Combined oral contraceptives reduce ovarian cancer risk by up to 50 % when used ≥5 years (CDC, 2022).
• Pregnancy & breastfeeding: Full‑term pregnancies and extended lactation are protective against endometrial and ovarian cancers.
• Screening for high‑risk individuals:
  • Annual transvaginal ultrasound + CA‑125 for women with BRCA mutations (per NCCN guidelines).
  • Consider prophylactic risk‑reducing salpingo‑oophorectomy after childbearing for carriers of BRCA1/2.
  • Endometrial biopsy surveillance for women with Lynch syndrome.
• Avoid tobacco and limit alcohol intake (< 1 drink/day).

Complications

If left untreated or when disease progresses, several serious complications can arise.

• Ascites: Fluid buildup in the abdomen causing distension, shortness of breath, and risk of infection.
• Bowel obstruction: Tumor invasion or adhesions leading to abdominal pain, vomiting, and inability to pass gas.
• Deep vein thrombosis (DVT) / Pulmonary embolism: Cancer‑associated hypercoagulability increases clot risk.
• Metastatic spread: To lungs, liver, brain, or bone, causing organ‑specific symptoms.
• Secondary cancers: Prior radiation or certain chemotherapies can raise risk of leukemia or other solid tumors.
• Psychological impact: Depression, anxiety, and fear of recurrence are common and require active management.

When to Seek Emergency Care

---

References: Mayo Clinic, CDC, National Cancer Institute, World Health Organization, NCCN Clinical Practice Guidelines (2023), American College of Obstetricians and Gynecologists, Cleveland Clinic. All information is for educational purposes and does not replace professional medical advice.

```